87 results about "Myosin" patented technology

The invention provides an application of dihydroflavonoid compound naringin in promoting proliferation and differentiation of porcine muscle stem cells to form myotubes, which is characterized in that the naringin is added into a DMEM / F12 culture medium containing 15% of fetal calf serum and 1% of double antibodies and a DMEM differential culture medium containing 2% of horse serum and 1% of double antibodies until the final concentration is 70 mu M, and the porcine muscle stem cells are respectively treated in proliferation and differentiation stages, hoechst 33342 staining and immunofluorescence staining methods are used for respectively judging the number of cells in the proliferation stage and the fluorescence area, fluorescence intensity and nuclear fusion rate of Myosin in myotubes formed in the differentiation stage. The relative proliferation multiple of the muscle stem cells treated by adding naringin and the fluorescence area, the fluorescence intensity and the nuclear fusion rate of Myosin in myotubes are obviously higher than those of a blank control group. By adopting the method, proliferation and differentiation of the porcine muscle stem cells can be promoted, and a new thought is provided for maintaining cell dryness and large-scale production of cultured meat.

The invention discloses an early diagnosis and early screening kit for joint detection of Parkinson's disease and application of the kit, and relates to the technical field of medical treatment. The kit is used for combined detection of three proteins, namely alpha synuclein (alpha-Syn), tyrosine 3-monooxygenase / tryptophan 5-monooxygenase activated protein zeta (YWHAZ) and myosin light chain 6 (Myl6), immunochromatography, chemiluminescence and other methods and a double-antibody sandwich method are adopted, the diagnosis efficiency of the YWHAZ protein is prominent, the AUC reaches 0.96, and the detection sensitivity is high. The AUC of Myl6 is 0.92, the AUC of alpha-Syn is 0.82, the joint detection AUC is up to 0.98, the kit is newly added with a time-resolved fluorescence immunochromatography technology, low-background and high-sensitivity detection is realized through a lanthanide-labeled antibody, the change of related protein expression level can be detected in the early stage of Parkinson's disease, early screening and diagnosis are realized, and the kit has the advantages of high specificity, joint detection up to 95%, high sensitivity, high sensitivity and the like. The joint detection reaches 96%, the operation is simple and convenient, and the sample requirement is low.

Methods of treatment with a myosin inhibitor using protein levels; methods of monitoring response to treatment based on such protein levels; and methods of determining whether to treat a patient with a myosin inhibitor based on such protein levels are described herein. Such methods may include obtaining a biological sample of a subject, measuring one or more protein levels in the sample, analyzing the one or more protein levels, and determining the treatment response based on the analysis, and may further include treating the subject based on the determination of treatment response.

The invention discloses a pyrimidinedione derivative as well as a preparation method and application thereof. Molecules of the pyrimidinedione derivative have better myosin inhibitory activity, also have antioxidant effects of DPPH and / or MDA and the like and anti-ferroptosis activity, and can be applied to treatment / prevention of heart myosin, anti-oxidative stress and anti-ferroptosis mechanism related diseases. The diseases or symptoms mainly comprise hypertrophic cardiomyopathy, diastolic heart failure, left ventricular hypertrophy, heart diseases with pathophysiological characteristics related to the hypertrophic cardiomyopathy, or other disease states and conditions which are obvious to those skilled in the art, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof. Or a hydrate or solvate thereof, and a pharmaceutical composition containing the same.

Provided herein are quinazolinone compounds for modulating muscle myosin to treat obesity and related disorders such as cardiovascular diseases, type 2 diabetes, obstructive sleep apnea, cancer, and osteoarthritis.

The invention belongs to the technical field of food processing, and discloses application of muscle protein in a protein product, the protein product and a manufacturing method of the protein product. The protein product comprises the following components in parts by weight: 1-5 parts of recombinant myosin; and 5-9 parts of animal protein or vegetable protein. The recombined muscle protein is creatively adopted to improve the texture and flavor of the plant meat, and experiments prove that the recombined muscle protein (FW protein) can perfectly simulate the texture of a real meat product after being subjected to simple cross-linking treatment, and meanwhile, the recombined muscle protein has the function of a protein-based adhesive. Animal protein in meat products can be completely or partially replaced, dependence on animal husbandry is remarkably reduced, and the sustainable food production requirement is met. In the hot processing (such as extrusion and cooking) process, the recombinant muscle protein can form a stable three-dimensional network structure, so that the product is endowed with good elasticity and slicing property, the problems of loose texture and fragility of the traditional vegetable protein product are solved, the use of additives is reduced, and the production process is simplified.

The present application relates to the technical field of health care products, in particular to a pelvic floor muscle repairing composition containing supermolecular tightening Dropsordry and a preparation method thereof, which comprises the following components in mass fraction: 10-14 parts of protein composition, 20-24 parts of chitosan modified Dropsordry, 5-7 parts of freeze-dried powder of Lactobacillus bulgaricus, 10-12 parts of hyaluronic acid, 6-8 parts of glycine and 15-17 parts of proline; each part of the protein composition comprises 20-30 parts of myosin, 30-34 parts of actin, 5-10 parts of hydrolyzed collagen and 240-280 parts of deionized water. The pelvic floor muscle repairing composition can reduce drug toxicity, reduce the amount of drug administration, continuously supplement the required elements of the body during treatment, and quickly relieve the constipation problem caused by the functional damage of the pelvic floor muscle.

In one aspect, the disclosure relates to pharmaceutical compositions containing LPAR5 agonists including, but not limited to, compounds and methods for treating diseases and disorders associated with a mutation in Myosin Vb (MYO5B), decreased lysophosphatidic acid receptor 5 (LPAR5) expression, or both using the same. In one embodiment, the disclosed compositions and kits may be particularly useful in treating microvillus inclusion disease (MVID) and the diarrhea and malabsorption associated with the same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The present invention relates to a pyridazinone derivative and a use thereof. Specifically, the present invention relates to a compound represented by general formula (I), a preparation method therefor, a pharmaceutical composition thereof, and a use of the compound represented by general formula (I) or the pharmaceutical composition thereof in the preparation, prevention and / or treatment of Myosin-mediated diseases, wherein each substituent in general formula (I) is as defined in the description.

The disclosure provides polynucleotides containing regions of the Myosin 15 (Myo15) promoter, as well as vectors containing the same, that can be used to promote expression of a transgene specifically in hair cells. The polynucleotides described herein may be operably linked to a transgene, such as a transgene encoding a therapeutic protein, so as to promote hair cell-specific expression of the transgene. The polynucleotides described herein may be operably linked to a therapeutic transgene and used for the treatment of subjects having or at risk of developing hearing loss or vestibular dysfunction.

The present application relates to a freshness indicator protein related to quality traits of low-temperature stored Siniperca chuatsi, endogenous proteases and applications. The freshness indicator endogenous proteases are related to postmortem proteolysis and meat softening of Siniperca chuatsi, including cathepsin B, cathepsin L and calpain. The freshness indicator proteins are related to quality changes occurring during postmortem cold storage of Siniperca chuatsi, including myoactin 1, myosin binding protein, LDB protein, actin-related protein, etc. The present application determines the change rule of endogenous protease activity of Siniperca chuatsi at different storage stages, and the dynamic influence on muscle proteolysis and muscle degradation of Siniperca chuatsi, and reveals the internal relationship with fish meat sensory quality and processing characteristics, and clearly defines the "critical point" of quality deterioration of Siniperca chuatsi. It provides clear guidance for the control of endogenous enzyme-mediated quality deterioration in the processing and storage process of Siniperca chuatsi.

The invention discloses a beef myosin flavor peptide CM1, the amino acid sequence of the beef myosin flavor peptide CM1 is EDMAE, and the molecular weight of the flavor peptide is 594 Da. The flavor peptide belongs to umami peptide, the umami threshold value of the flavor peptide is smaller than the umami threshold value of monosodium glutamate, the flavor peptide has good umami and umami enhancing characteristics, the umami characteristics of monosodium glutamate, soy sauce and soup can be remarkably improved, the flavor peptide can be used as a novel seasoning for replacing monosodium glutamate, the umami and mellowness of the whole taste of food are improved, and the flavor peptide has good market application prospects.

Provided herein are quinolinone compounds for modulating muscle myosin to treat obesity and related disorders such as cardiovascular diseases, type 2 diabetes, obstructive sleep apnea, cancer, and osteoarthritis.

Described herein are methods of treatment with myosin inhibitors based on protein levels; methods of monitoring response to treatment based on such protein levels; and methods of determining whether to treat a patient with a myosin inhibitor based on such protein levels. Such methods may include obtaining a biological sample of a subject, measuring one or more protein levels in the sample, analyzing the one or more protein levels, and determining the therapeutic response based on the analysis, and may also include treating the subject based on the determination of a therapeutic response.

Disclosed in the present invention are a benzo-cyclic compound represented by formula (I), or a stereoisomer or a pharmaceutically acceptable salt and a pharmaceutical composition comprising same, and a use thereof in the preparation of a drug for treating / preventing a Myosin II-mediated disease, wherein groups in formula (I) are as defined in the description.

The invention discloses the technical field of animal cell culture and cell culture meat, and provides a food-grade natural compound combination method for promoting efficient myogenic differentiation in vitro. According to the method disclosed by the invention, a combination of xanthophyll and arachidic acid is added into a basic myogenic differentiation induction culture medium to form a myogenic differentiation promoting culture medium. According to the myogenic differentiation culture medium system, the myogenic differentiation efficiency of the myogenic cells can be improved from about 23% to 45% or above, the myogenic fusion efficiency can be improved from about 18% to 33% or above, the problems that the in-vitro differentiation efficiency of the myogenic cells is low, the content of key proteins such as myosin is insufficient and the like are effectively solved, and the myogenic differentiation culture medium system is suitable for large-scale popularization and application. And a feasible scheme is provided for large-scale muscle fiber production of cell culture meat.

The disclosure provides polynucleotides containing regions of the Myosin 15 (Myo15) promoter, as well as vectors containing the same, that can be used to promote expression of a transgene specifically in hair cells. The polynucleotides described herein may be operably linked to a transgene, such as a transgene encoding a therapeutic protein, so as to promote hair cell-specific expression of the transgene. The polynucleotides described herein may be operably linked to a therapeutic transgene and used for the treatment of subjects having or at risk of developing hearing loss or vestibular dysfunction.

The disclosure provides polynucleotides containing regions of the Myosin 15 (Myo15) promoter, as well as vectors containing the same, that can be used to promote expression of a transgene specifically in hair cells. The polynucleotides described herein may be operably linked to a transgene, such as a transgene encoding a therapeutic protein, so as to promote hair cell-specific expression of the transgene. The polynucleotides described herein may be operably linked to a therapeutic transgene and used for the treatment of subjects having or at risk of developing hearing loss or vestibular dysfunction.

A composition and method for transdifferentiating non-neuronal cells into neurons. Disclosed is a composition for inducing cell transdifferentiation, comprising a Myosin inhibitor, and an isoxazole compound and / or its derivatives. Also disclosed is a method for inducing non-neuronal cells to transdifferentiate into neurons, comprising: culturing non-neuronal cells in an induction culture medium comprising a Myosin inhibitor, and then culturing them in a maturation culture medium comprising a Myosin inhibitor and an isoxazole compound and / or its derivatives until mature neurons are obtained. Also disclosed is a use of the composition in inducing non-neuronal cells to transdifferentiate into neurons, and a method for transdifferentiating non-neuronal cells in a subject into neurons, comprising administering an effective amount of a Myosin inhibitor and an isoxazole compound and / or its derivatives to the subject. The method of the present application is simple, requiring only two simple small molecule combination treatments, without the need for regulation by overexpression of specific genes, and can be performed efficiently both in vivo and in vitro, thereby achieving simple and efficient neuronal regeneration.

The invention is suitable for the technical field of cosmetic preparations, and provides a composite polypeptide composition and a preparation method thereof. The composition is prepared from the following raw materials in parts by weight: 20 to 40 parts of mussel mucin derived peptide, 10 to 20 parts of carnosine, 20 to 35 parts of polylysine-oligopeptide 1-lactitol-sodium citrate assembly, 30 to 50 parts of fermented centella asiatica extract, 10 to 30 parts of leontopodium alpinum stem cell extract, 100 to 200 parts of phospholipid, 30 to 60 parts of cholesterol and 100 to 150 parts of emollient. The preparation method comprises the following steps: dissolving fat-soluble and partial active components by using an organic phase, dispersing or dissolving water-soluble active components and an assembly by using a water phase, and carrying out rotary evaporation film formation, hydration and high-pressure homogenization to prepare the nano co-assembled lipid carrier. Through component synergy and a nano-carrier technology, the entrapment efficiency and stability of active components are remarkably improved, the skin permeability is enhanced, the synergistic effects of moisturizing, skin barrier repairing and aging resisting are achieved, and the composition is suitable for preparing various cosmetics.

The present invention relates to novel blood-brain barrier (BBB) ​​permeable substituted bicyclic derivatives capable of selectively inhibiting myosin light chain phosphate phosphorylation mediated by ROCK2 and / or Rho kinase, compositions comprising such derivatives, methods for preparing such derivatives and / or compositions, and methods for using such derivatives and / or compositions.

The invention relates to the technical field of microorganisms, and particularly discloses a bifidobacterium breve BB18 and an application of an exopolysaccharide BB18-EPS (extracellular polysaccharide) produced by the bifidobacterium breve BB18. The strain is preserved in the China General Microbiological Culture Collection Center on June 9, 2025, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.34621. The exopolysaccharide BB18-EPS secreted by the strain can be used as a food additive for gel modification of shrimp myofibrillar protein (MP), and the product performance is remarkably improved. Experiments prove that BB18-EPS drives ordered crosslinking of myosin through a hydrophobic effect, promotes transformation of a secondary structure of MP to alpha-helix, and optimizes the recombination efficiency of a molecular chain; meanwhile, through interaction of hydroxyl, sugar residues and water molecules, the density of a gel network is enhanced, and the thermal stability and the deformation resistance are improved. The composite gel system can be applied to the fields of minced penaeus vannamei products and the like, and the product texture and the processing yield are effectively improved.

The present disclosure relates to the use of split inteins for expressing Myosin-VIIa protein encoded by MYO7A gene in a subject in need thereof for gene therapy in particular for the treatment of MYO7A associated disease, preferably Usher syndrome type 1B.

The invention discloses a pressure cooking utensil, a cooking control method of the pressure cooking utensil and a computer readable storage medium, the pressure cooking utensil comprises a pot, a sealing cover body and a pressurization module, the pot is provided with a heating module, the pot cover is provided with an exhaust valve, and the cooking control method of the pressure cooking utensil comprises the following steps: starting the pressurization module; the pressurizing module is used for pressurizing the cooker, so that the pressurizing module inputs gas into the cooker to increase the pressure in the cooker; when the air pressure value in the cookware reaches the limited pressure, the pressurization module is closed, and the heating module is controlled to heat the cookware; and controlling the exhaust valve to exhaust so that the air pressure value in the cooker is constantly maintained within the limited pressure range. According to the technical scheme, pressure-maintaining cooking of the pressure cooking utensil is achieved, dissolution of muscle protein of meat food materials is reduced, the tenderness of the food materials is improved, and the practicability and reliability of the pressure cooking utensil are further improved.

This invention pertains to the pharmaceutical field and relates to a class of substituted indene compounds and their uses. Specifically, this invention relates to compounds of formula (I), or stereoisomers, tautomers, nitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts, or prodrugs of compounds of formula (I). The compounds and pharmaceutical compositions thereof involved in this invention, as myosin inhibitors, can be used to prepare medicaments for the prevention or treatment of myosin-related diseases, and particularly for the treatment of hypertrophic cardiomyopathy.

The application discloses a benzisothiazole carboxamide compound and application thereof. The benzisothiazole carboxamide compound has the characteristics of high specificity and high activity as an inhibitor of myosin motor domain, and can significantly inhibit the growth and development process and pathogenicity of pathogenic fungi, especially Pyricularia oryzae.

The invention discloses an application of a haplotype of a megalobrama amblycephala body weight associated SNP site in breeding, and belongs to the technical field of aquatic breeding. The haplotype is randomly formed by a haplotype I, a haplotype II and a haplotype III, basic groups at positions 457 and 770 of a myosin IB gene of the haplotype I are A and G respectively, basic groups at positions 457 and 770 of the myosin IB gene of the haplotype II are A and C respectively, basic groups at positions 457 and 770 of the myosin IB gene of the haplotype III are T, C, T and C respectively, and basic groups at positions 770 and 770 of the myosin IB gene of the haplotype III are A and G respectively. Compared with other diplotypes, the homozygous double V type randomly formed by the haplotype III has remarkable advantages in average weight and myosin IB gene expression, and can be used for auxiliary breeding of megalobrama amblycephala fast-growing new line molecules.

The invention relates to a triazine diketone derivative, a preparation method thereof and application of the triazine diketone derivative in medicine. Specifically, the invention relates to a triazine diketone derivative as shown in a general formula (I), a preparation method of the triazine diketone derivative, a pharmaceutical composition containing the triazine diketone derivative and application of the triazine diketone derivative as a therapeutic agent. The invention relates to the field of medicines, in particular to the use in preparing a myosin inhibitor and the use in preparing a medicine for treating hypertrophic cardiomyopathy (HCM) or heart diseases with pathophysiologic characteristics related to the HCM. # imgabs0 #

The invention relates to the technical field of food freezing, in particular to a food antifreeze agent and a preparation method and application thereof. The food antifreeze agent comprises carboxymethyl chitosan (CMCh) and basic amino acid. The food antifreeze agent is a binary compound system designed according to the'head and tail 'structural characteristics of myosin, a complementary synergistic mechanism of'head targeting enhancement + tail precise regulation' is formed, the food antifreeze agent has a very good antifreeze effect, and effective antifreeze can be achieved by only 0.5% (by weight) of the antifreeze agent.